LSE:DEST (Destiny Pharma Plc)

About DEST

Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. Its products include XF drug series, XF-73 and Pipeline. The company was founded by Suzanne Brewer, Kevin Brewer and William Guy Love on March 4, 1996 and is headquartered in Brighton, the United Kingdom.